Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06496243 · ClinicalTrials.gov registry record · Phase 2

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

A Phase 2 study of Dyslipidemias, sponsored by NewAmsterdam Pharma.

Recruiting
Registry status
Phase 2
Development phase
69
Enrollment target
1
Study location

NCT06496243 is a Phase 2 study of Dyslipidemias that is actively recruiting participants, run by NewAmsterdam Pharma. The registered enrollment target is 69 participants, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06496243, a Phase 2 study of Dyslipidemias, is actively recruiting participants, sponsored by NewAmsterdam Pharma.

RECRUITING
Registry status
Phase 2
Development phase
69 participants
Enrollment target
1
Study location

Study Summary

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Conditions Studied

Dyslipidemias

Interventions

  • DRUG obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks

Study Locations (1)

Pennsylvania

  • UPenn - Philadelphia

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2024-12-02
Est. Completion 2026-02
Phase Phase 2

Sponsor

NewAmsterdam Pharma

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06496243

The ClinicalTrials.gov registry entry for NCT06496243 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower). The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 1 intervention - of which obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks is the first listed.

NCT06496243 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06496243 about?

NCT06496243 is a clinical study titled "Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels". The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 T...

What is the current status of trial NCT06496243?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2024-12-02. Estimated completion is 2026-02.

What conditions does trial NCT06496243 study?

This clinical trial studies the following conditions: Dyslipidemias.

What interventions are being tested in trial NCT06496243?

The interventions under investigation include: obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks (DRUG).

Who is sponsoring clinical trial NCT06496243?

This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06496243 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dyslipidemias

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dyslipidemias

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.